ABIVAX SA Company Review & Valuation ABVX
About ABIVAX SA
ABIVAX SA, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. Its principal products include ABX 464 that is in Phase II clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS; ABX 203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX 196, an art immune enhancer candidate that has completed Phase I clinical trials for iNKT cells. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis. In addition, the company's pre-clinical programs comprise ABX 220 for the treatment of Dengue fever; ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and ABX 311 for the treatment of Chikungunya. ABIVAX SA has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute; and a partnership with the Cuban Centro de Ingeneria Genetica y de Biotecnologia. The company was incorporated in 2013 and is headquartered in Paris, France.
- Paris, France
Primary Stock Exchange Listings